Skipping Breakfast and Cardiovascular Risk

Several studies have associated skipping breakfast (having little to no breakfast) with increased cardiometabolic risk factors such as obesity, hypertension, dyslipidemia, diabetes and metabolic syndrome. 

Saltearse el desayuno y riesgo cardiovascular

This study examined all the available evidence on the association of skipping breakfast and cardiovascular and all-cause mortality.

It included 4 studies with close to 200,000 adults (mean age ≥40, 48.5% women) with no known cardiovascular disease at recruiting, followed up for mean 17.4 years.

The general analysis suggests that the population which regularly skips breakfast has 21% higher risk of CAD or cardiac death (HR 1.21, CI 95% 1.08 to 1.35; p=0.304) than those that regularly have breakfast.


Read also: Egg Consumption and Mortality Due to Cardiovascular Events.


Even all cause death risk was 32% higher in patients that skip breakfast (HR 1.32, CI 95% 1.17 to 1.48; p=0.339).

Looking closer, we find that the definition of “no breakfast” was heterogeneous between the studies and that the populations were also different, which might have led to misleading outcomes, regardless adjustments. 

Robust data call for further study at long term with consistent definitions of “no breakfast”. 


Read also: Artificially Sweetened Beverages and Alzheimer Risk.


Meanwhile, it seems reasonable (within the primary prevention scope) to recommend our patients have breakfast, which should the most important meal. 

2020-01-16-jcdd-06-00030

Original Title: Skipping Breakfast and the Risk of Cardiovascular Disease and Death: A Systematic Review of Prospective Cohort Studies in Primary Prevention Settings.

Reference: Richard Ofori-Asenso et al. J Cardiovasc Dev Dis 6 (3) 2019 Aug 22.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...

TAVR and Anticoagulation: What Should We Do?

Transcatheter aortic valve replacement (TAVR) has consolidated as a valid strategy for certain groups of patients. However, approximately one third of those who require...

Direct Oral Anticoagulants for Ventricular Thrombus After STEMI

While the incidence of intracavitary thrombi after acute myocardial infarction (AMI) has decreased thanks to optimized primary angioplasty times, some studies report rates of...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...